MORRISVILLE, N.C., August 16, 2021 – Myocardial Solutions (“MSI”) announced the launch of their new dynamic website Monday to support the growing commercial and clinical initiatives to drive MyoStrain adoption. The newly updated website features an improved content management system, providing a single destination for healthcare professionals and investors to receive the latest developments regarding MyoStrain and the company.
Among the main new additions to the website is the medical affairs page, which includes the clinical training pathway to help train and certify physicians to use MyoStrain in their practice. Physicians will be able to complete a registration form and speak directly with a medical affairs representative for further instructions.
The new website also includes physician testimonials, clinical presentations from global events and conferences, and new clinical applications, such as COVID-19. The website also adds new search functionality for easier access to new and old MyoStrain content, as well as a new email alert sign-up option for instant notifications about new company developments. MSI expects to bring additional content within the fiscal year, expanding on the current education initiative by providing clinical case studies, blogs, media coverage, brochures and more over time.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 500 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.